Recombinant Human IL2RA Protein, Fc-tagged, FITC conjugated
|Product Overview :||FITC conjugated recombinant human IL2RA α chain (NP_000408.1) precursor (Met 1-Cys 213), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cell.|
- Gene Information
- Related Products
|Molecular Mass :||The mature recombinant human IL2Rα/Fc is a disulfide-linked homodimeric protein generated by proteolytic removal of the signal peptide. The reduced monomer consists of 430 amino acids and has a predicted molecular mass of 48.5 kDa. In SDS-PAGE under reducing conditions, the apparent molecular mass of rhIL2Rα/Fc monomer is approximately 72 kDa due to glycosylation.|
|Endotoxin :||< 1.0 EU/ μg of the protein as determined by the LAL method.|
|Characteristic :||Disulfide-linked homodimer
Labeled with FITC via amines
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
|Stability :||Samples are stable for up to 12 months from date of receipt at -70 centigrade.|
|Storage :||Store it under sterile conditions at -20 to -70 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.|
|Storage Buffer :||Lyophilized from sterile PBS, pH 7.4|
|Reconstitution :||It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4 centigrade before opening to recover the entire contents.|
|Gene Name :||IL2RA interleukin 2 receptor, alpha [ Homo sapiens ]|
|Official Symbol :||IL2RA|
|Gene ID :||3559|
|mRNA Refseq :||NM_000417|
|Protein Refseq :||NP_000408|
|UniProt ID :||P01589|
|◆ Recombinant Protein|
|IL2RA-2068R||Recombinant Rhesus Macaque IL2RA Protein, His (Fc)-Avi-tagged||+Inquiry|
|IL2RA-320H||Recombinant Human IL2RA Protein, Fc-tagged||+Inquiry|
|IL2RA-5199H||Recombinant Human IL2RA Protein||+Inquiry|
|IL2RA-365C||Recombinant Cynomolgus Monkey IL2RA Protein, His (Fc)-Avi-tagged||+Inquiry|
|IL2RA-5198H||Recombinant Human IL2RA Protein||+Inquiry|
|IL2RA-2907HCL||Recombinant Human IL2RA cell lysate||+Inquiry|
|IL2RA-1015CCL||Recombinant Cynomolgus IL2RA cell lysate||+Inquiry|
|IL2RA-2024MCL||Recombinant Mouse IL2RA cell lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The combination of IL2RA and other drugs may produce nausea, vomiting, rash and other adverse reactions, should be monitored.
The frequency of use of IL2RA depends on the specific situation of the patient, and is generally used 1-3 times per week.
IL2RA, in the right dosage and frequency of use, can significantly relieve symptoms of diseases such as autoimmune diseases and organ transplant rejection.
Can assist in the treatment of some types of malignant tumors, but it is not a complete cure for cancer.
The effective rate of IL2RA therapy depends on many factors such as the type of disease, the patient's condition and the treatment regimen, and the effective rate is generally between 50% and 90%.
Indications of IL2RA include a variety of autoimmune diseases, organ transplant rejection and malignant tumors.
Customer Reviews (3)Write a review
Structural stability of IL2RA, that is, whether it can maintain its structural integrity and functional activity under different conditions such as temperature, pH value and storage time, HPLC, CD spectroscopy and other techniques can be used to evaluate the stability. -
Solubility and stability of IL2RA in physiological buffers to ensure its reliability in practical applications. -
To evaluate whether IL2RA has biological activity, we can verify its IL-2 binding ability and signal transduction ability through cell experiments, which are the key functions of IL2RA. -
Ask a Question for All IL2RA Products
Required fields are marked with *
My Review for All IL2RA Products
Required fields are marked with *